Non-Fermentative Gram-negative Bloodstream Infection in Northern Italy: a Multicenter Cohort Study.

Renato Pascale (renato.pascale@aosp.bo.it)  
Universita degli Studi di Bologna Scuola di Medicina e Chirurgia  
https://orcid.org/0000-0003-2687-4235

Silvia Corcione  
University of Turin

Linda Bussini  
University of Bologna

Livia Pancaldi  
University of Bologna

Daniele Roberto Giacobbe  
University of Genoa

Simone Ambretti  
University of Bologna

Tommaso Lupia  
University of Turin

Cristina Costa  
University of Turin

Anna Marchese  
University of Genoa

Francesco Giuseppe De Rosa  
University of Turin

Matteo Bassetti  
University of Genoa

Claudio Viscoli  
University of Genoa

Michele Bartoletti  
University of Bologna

Maddalena Giannella  
University of Bologna

Pierluigi Viale  
University of Bologna
Abstract

Background: The management of non-fermentative gram-negative bloodstream infection (NFGN-BSI) offers numerous challenges. In this study the aim is to analyse a large cohort of patients with NFGN-BSI recruited in the northern Italy to describe epidemiology, etiological and susceptibility pattern, therapeutic management and outcome.

Methods: Multicentre retrospective cohort study of patients hospitalised at three large teaching hospitals in northern Italy in a fourth year period.

Results: 355 BSI episodes were analyzed, due to P. aeruginosa (72.7%), A. baumannii (16.6%), and Stenotrophomonas maltophilia (10.7%). Overall, 21.4% of isolates were defined as DTR, highest rate among A. baumannii (64.4%). All-cause 30-day mortality rate was 17.5%. Rates of XDR or DTR A. baumannii isolation were significantly higher in non-surviving patients. Independent risk factors for 30-day mortality were: age (HR 1.03, 95%CI 1.00-1.04, p=0.003), septic shock (HR 2.84, 95%CI 1.67-4.82, p<0.001) and BSI due to Acinetobacter baumannii (HR 2.23, 95%CI 1.27-3.94, p=0.005).

Conclusion: The overall prevalence of DTR was high in the NFGN BSI cohort analyzed, mainly among Acinetobacter baumannii episodes (64.4%). Acinetobacter baumannii is showed to be an independent predictor of mortality. These evidences marked the urgent need of new therapeutic options against this pathogen.

Trial registration number: 79/2017/O/OssN. Approved: March 14th, 2017.

Background

The management of non-fermentative gram-negative bloodstream infection (NFGN-BSI) offers numerous challenges. Indeed, there are several clinical and microbiological issues that may contribute to its high morbidity and mortality. NFGN-BSI is usually diagnosed in people with severe underlying conditions, critically ill and/or immunocompromised patients [1-3]. Isolates are generally resistant, or prone to acquire resistance, to first-line antibiotics resulting in a high rate of initial inappropriate therapy and/or in the use of less effective and more toxic drugs. To counteract these findings, antibiotic combination regimens are frequently employed with controversial results in terms of efficacy, toxicity and collateral environmental damage [3, 4].

The knowledge of local epidemiology, etiological distribution in terms of causative agents and antibiotic resistance, therapeutic approach and factors associated with poor outcome are useful to guide infection control and antimicrobial stewardship policies and to inform clinicians regarding the best treatment approach [4].

With this premise, we analysed a large cohort of patients with NFGN-BSI recruited in three regions of northern Italy to describe the current epidemiology, etiological and susceptibility pattern distribution,
therapeutic management and outcome.

Methods

Study design and setting

Multicentre retrospective cohort study of patients hospitalised at three large teaching hospitals in northern Italy: i) Sant’Orsola Malpighi Hospital, Bologna; ii) City of Health and Sciences, Molinette Hospital, Turin; iii) San Martino Hospital, Genoa. The study period was from January 1st 2013 to December 31st 2016. Patients were identified through the records of the Microbiology Laboratory of each hospital.

Clinical charts and hospital records were reviewed, until 90 days after the index blood cultures (BCs), to gather study variables using a pre-established case report form. A local senior investigator systematically checked data for accuracy before they were recorded into a database. In addition, the numbers of patient days per year were recorded to assess the incidence of NFGN-BSI in the participating hospitals during the study period.

Ethic Committees of each centre approved the study, waiving of informed consent was obtained due to the retrospective non-interventional study design. Data were collected anonymously.

Participants

Inclusion criteria were all adult (≥18 years) patients diagnosed with NFGN-BSI, defined as one or more positive BCs obtained from a patient suspected of having infection. Patients were considered only once at the time of first episode (index BCs).

Exclusion criteria included: (i) polymicrobial BSI, defined as growth of more than one micro-organism, excluding potential contaminants (i.e. coagulase-negative staphylococci, Corynebacterium spp., Propionibacterium spp.); (ii) clinical data not available.

Variables and definitions

The primary outcome was all-cause mortality within 30 days after index BCs [5].

Predictor variables included: age, sex. Underlying diseases were assessed according to the Charlson comorbidity index [6]. Immunosuppression included neutropenia (neutrophil count <500/mm3), solid organ transplantation, hematopoietic stem cell transplantation, corticosteroid therapy at a dosage higher then or equivalent to prednisone 16 mg/day ≥ 15 days, uncontrolled HIV infection (<200 CD4/mm3).

BSI was classified according to the site of acquisition into nosocomial, healthcare-associated and community acquired using Friedman's criteria [7]. Clinical severity at infection onset was assessed according to SOFA score and new septic shock criteria [8]. BSI sources were established according to
Centers for Disease Control and Prevention (CDC) criteria [9]. In the absence of a recognized source, BSI was considered as primary. BSI was defined as complicated when the infection source was not fully removable.

The susceptibility pattern of isolates was classified according to Magiorakos et al. criteria [10] as non-MDR, MDR, XDR or PDR.

In addition, CDC surveillance definitions were used to assess susceptibility to carbapenems, extended-spectrum cephalosporins (ESC) and fluoroquinolones (FQ) (https://gis.cdc.gov/grasp/PSA/Downloads/AR-PhenotypeDefinitions.pdf). Moreover susceptibility to betalactam/betalactamase inhibitors (BL/BLI) and colistin was determined according to European Committee for Antimicrobial Susceptibility Testing (EUCAST) criteria.

Finally the new definition of “difficult to treat resistance” (DTR) was also assessed as reported elsewhere [11, 12] Empirical therapy was defined as antibiotics administered before the susceptibility report was available. It was considered appropriate when at least one in vitro active drug (according to the susceptibility pattern of the isolate) was administered within 24 h after drawing index BCs. Delayed or no active antibiotic administration within this period was considered as inappropriate empirical therapy.

Definitive antibiotic therapy was defined as antibiotic treatment administered according to susceptibility results. Antibiotic regimens including more than one anti-gram-negative agents, irrespective of their in vitro activity against the BSI isolate, during more than 50% of treatment duration were defined as “combination regimen”. Antibiotic therapy including at least two drugs showing in vitro activity against the BSI isolate was labelled as “2-in vitro active combination regimen”. Duration of antibiotic treatment was defined as the number of consecutive days during which the patient received an appropriate antibiotic regimen. Source control was defined as the removal of the infection source within 7 days of index BCs, including the performance of non-surgical or surgical procedures to treat an obstructive focus or abscess at any site including, among others, the urinary tract, biliary tract and surgical site, and the removal of any device deemed as the source of BSI.

Microbiology

BCs were incubated using the BACTEC FX Automated Blood Culture System (Becton Dickinson, Franklin Lakes, NJ). All positive BCs were processed with Maldi Biotyper MALDI-TOF system (Bruker Daltonics, Bremen, Germany) for rapid and reliable species identification of microorganisms. Antimicrobial susceptibility testing was performed using the Vitek 2 automated system (bioMerieux, Marcy l’Etoile, France) in two hospitals (Bologna and Genova) and the MicroScan system in the remaining hospital (Torino). The minimum inhibitory concentrations (MICs) were interpreted using EUCAST clinical breakpoints for all tested antibiotics.

Statistical analysis
For the descriptive analysis, categorical variables were presented as absolute numbers and their relative frequencies. Continuous variables were presented as the mean and standard deviation if normally distributed or as the median and interquartile range (IQR) if non-normally distributed.

Risk factors for all-cause 30-day mortality were analysed by univariate and multivariate analysis. Categorical variables were compared using $\chi^2$ or Fisher exact test when appropriate. Continuous variables were compared using the Mann–Whitney U-test. Significant and clinically relevant covariates identified in univariate analysis were introduced into a multivariable Cox regression survival model after verifying for proportional hazards and collinearity. Significance was considered for $p<0.05$. All the analysis were performed using SPSS software.

Results

Over the study period, 527 patients were diagnosed with NFGN-BSI. Of them, 172 were excluded: 146 patients had polymicrobial bacteremia, and for the remaining 26 patients clinical data were not available. Thus, 355 patients (177 from Bologna, 155 from Turin and 23 from Genova) were analysed (Figure 1).

The overall incidence of *Pseudomonas aeruginosa* BSI per 1000 patient days was 0.12, 0.12, 0.17, and 0.23 in 2013, 2014, 2015 and 2016, respectively. It was similar between participating hospitals. The overall incidence of *Acinetobacter baumannii* BSI per 1000 patient days was 0.02, 0.03, 0.06, and 0.04 in 2013, 2014, 2015 and 2016, respectively. It was similar between participating hospitals. Data shown in Figure 2.

Etiological distribution and susceptibility patterns are shown in Table 1. Most episodes were due to *P. aeruginosa* (n=258, 72.7%), followed by *A. baumannii* (n=59, 16.6%), and *Stenotrophomonas maltophilia* (n=38, 10.7%). Overall, 21.4% of isolates were defined as DTR with highest rate among *A. baumannii* (64.4%). Susceptibility rates to individual antibiotic categories are shown in Figure 3. Both *P. aeruginosa* and *A. baumannii* maintained high rate susceptibility to colistin.

The general characteristics of study population are shown in Table 2. Overall, 65.6% of patients were male, the median age was 67 (IQR 55-79) years, the median Charlson index was 5.7 (IQR 3.6-7.4), and 24.5% were immunocompromised. Most patients were hospitalized at a medical ward at BSI onset (59.2%), and the majority of episodes were hospital acquired (70.1%). Infection source was not identified in 183 (51.5%) cases, in the remaining cases the most common sources of NFGN-BSI were CVC (n=102) and lower respiratory tract (n=49).

As shown in Figure 4, data on empirical and definitive antibiotic therapy were available for 266 (75%) and 333 (94%) patients, respectively. Active therapy was administered in 35.2% and 73.8% of empiric and definitive cohort patients, respectively. Empiric combination regimens were used in 55 (15.5%) patients with a 2-*in vitro* active drugs in 16 (4.5%). Combination regimens were used in 32.4% of patients in the definitive cohort, 16.3% with 2-*in vitro* active drugs. Empiric and definitive antibiotic regimens according to isolates are shown in Supplemental Tables 1 and 2.
All-cause 30-day mortality rate was 17.5%. Relapse at 90 days was observed in 7 patients (2%) within a median of 30 days (IQR 17-50) after index BCs. Compared to patients who were alive at day 30 (Table 2), non-surviving patients exhibited higher age, Charlson index and SOFA score, and higher rate of septic shock. Rates of *A. baumannii*, XDR or DTR isolation were significantly higher in non-surviving patients, while the rates of *P. aeruginosa* isolation and empirical active therapy were higher among survivors. For definitive therapy, the use of any combination was associated with higher mortality while that of 2-*in vitro* active combination did not. At multivariate analysis adjusted for DTR, active empiric therapy, active targeted therapy and source control, the independent risk factors for all-cause 30-day mortality were: age (HR 1.03, 95%CI 1.00-1.04, p=0.003), septic shock (HR 2.84, 95%CI 1.67-4.82, p<0.001) and BSI due to *Acinetobacter baumannii* (HR 2.23, 95%CI 1.27-3.94, p=0.005).

**Discussion**

In our large cohort of NFGN-BSI we have found high rates of DTR and carbapenem resistance, especially among *A. baumannii*. Empirical active therapy administration was significantly higher in surviving patients at univariate analysis, however it was not confirmed at multivariate analysis. Combination therapy, also with 2 active drug, was not associated to improving surviving at multivariate analysis. Of note, *A. baumannii* isolation resulted as independent risk factors for mortality at multivariate analysis. In our cohort nosocomial infections accounted for a large majority of cases (70%), mainly CVC related and pneumonia, according to literature [13, 14]. Therefore, promote and improve infection control programs would play a critical role in reducing the rates of this kind of nosocomial infections.

The increasing importance of the NFGN bacteria is also related to their complex antimicrobial resistance profile. In our cohort carbapenem resistance showed high prevalence, with 31.8% and 64.4% rates for *P. aeruginosa* and *A. baumannii* respectively. We have also analysed the prevalence of the new definition DTR. This definition reflects the use of second-line agents with poorer therapeutic index, resulting in a better prediction of poor outcome. In our cohort, the overall prevalence of DTR was 21.1%. It varied across species being highest among *A. baumannii* BSI with rates of 64.4%. This value was much higher than data present in literature [11][15]. Similarly, DTR prevalence for *Paeruginosa* BSI, accounted for 13.6%, higher than the rates showed previously [11][15]. As expected, in *A. baumannii* strain, CR and DTR rates were comparable.

In our study active therapy did not result statistically associated with improved outcome as previously reported elsewhere. This finding deserves further investigation. Indeed, the classical way to define if an antimicrobial agent is useful to treat an infection is the MIC determination of strains. However, MIC determination have some concerns: i) clinical laboratories cannot determine MICs with sufficient accuracy owing to the assay variation in the MIC test especially when automated or semi-automated methods are used, ii) the MIC does not represent a concentration directly compared with in vivo concentration found during treatment; iii) bacterial growth conditions in vitro could be different from those in vivo [16]. Also, the in vitro activity of antimicrobial often does not reflect the clinical feasibility due to the specific pharmacokinetic/toxicodynamic profile of the drugs and the source of infection [17].
These considerations could explain why in our cohort active therapy seems not associated to improving surviving. Similar experiences were previously reported elsewhere [18].

In our study, *A. baumannii* was an independent predictor of mortality. This is line with the characteristics of this pathogen that is commonly responsible for severe opportunistic nosocomial infections mainly in hospitalized immunocompromised patients [1-3]. Additionally, the complex antimicrobial resistance profile and the limited therapeutic arsenal for this strain may explain this result. In this scenario, polymyxins remains *in vitro* the most active agent. However, the *in vitro* activity of polymyxins not reflect the clinical feasibility due to the suboptimal pharmacokinetic/toxicodynamic profile of this class [17].

Our study has a number of limitations. Although we have analysed a large cohort of patients in three different centres, the results could be influenced by the epidemiology of a restricted area of our country. Also, our cohort is from all large tertiary teaching hospital reflecting the complexity and epidemiology of patients managed in similar institutions. The retrospective collection of patient and microbiological data could have limited integrity and accuracy. However, a senior investigator and three young investigators revised all CRFs, and reconciled data reports and missing data with the medical records before including information in the database.

To conclude, the overall prevalence of DTR was high in our NFGN BSI cohort, mainly among *Acinetobacter baumannii* episodes. Furthermore, *Acinetobacter baumannii* is showed to be an independent predictor of mortality. These evidences marked the urgent need of new therapeutic options against this pathogen.

**Abbreviations**

BCs: blood cultures  
CDC: Centers for Disease Control and Prevention  
CR: carbapenem resistance  
CRFs: clinical report forms  
CVC: central venous catheter  
DTR: difficult to treat resistance  
ESC: extended-spectrum cephalosporins  
EUCAST: European Committee for Antimicrobial Susceptibility Testing  
FQ: fluoroquinolones  
IQR: interquartile range
MDR: multi drug-resistant
MIC: minimal inhibitory concentration
NFGN-BSI: non-fermentative gram-negative bloodstream infection
PDR: pan drug-resistant
SOFA score: sequential organ failure assessment score
XDR: extensively drug-resistant

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committees of all hospital involved. Trial registration number of the study is 79/2017/0/OssN. The study was approved in March 14th, 2017. This study used data collected from patient records while maintaining patient anonymity.

Consent for publication

Not applicable

Availability of data and materials

The original data and materials from this study are available from the corresponding author on reasonable request.

Competing interests

All authors no reported competing interests.

Funding

No external funding was received for the present study.

Authors' contributions

RP: data analysis and drafting the manuscript, SC: data collection, LB: data collection, LP: data collection, DRG: data collection, SA: support in data collection, TL: data collection, CC: support in data collection, AM: support in data collection, CV: support in study design, FGDR: support in study design, MB: manuscript revision, MG: study design, data analysis and manuscript revision, PV: study design and manuscript revision.

Acknowledgements
References

1. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. *Clin Microbiol Infect* 2007,13:560-578.

2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. *Antimicrob Agents Chemother* 2007,51:3471-3484.

3. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. *Clin Infect Dis* 2006,43 Suppl 2:S43-48.

4. Gniadek TJ, Carroll KC, Simner PJ. Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle. *J Clin Microbiol* 2016,54:1700-1710.

5. Harris PNA, McNamara JF, Lye DC, Davis JS, Bernard L, Cheng AC, et al. Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. *Clin Microbiol Infect* 2017,23:533-541.

6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987,40:373-383.

7. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. *Ann Intern Med* 2002,137:791-797.

8. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016,315:801-810.

9. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008,36:309-332.

10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012,18:268-281.

11. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. *Clin Infect Dis* 2018,67:1803-1814.

12. Giannella M, Bussini L, Pascale R, Bartoletti M, Malagrino M, Pancaldi L, et al. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections. *Open Forum Infect Dis* 2019,6:ofz505.

13. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. *Clin Microbiol Rev* 2008,21:538-582.
14. McCann E, Srinivasan A, DeRyke CA, Ye G, DePestel DD, Murray J, et al. Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study. *Open Forum Infect Dis* 2018, *5*: ofy241.

15. Huh K, Chung DR, Ha YE, Ko JH, Kim SH, Kim MJ, et al. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. *Clin Infect Dis* 2020.

16. Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J. MIC-based dose adjustment: facts and fables. *J Antimicrob Chemother* 2018, *73*: 564-568.

17. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? *Clin Infect Dis* 2006, *42*: 1764-1771.

18. Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, et al. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study. *Clin Infect Dis* 2018, *67*: 1815-1823.

**Tables**

**Table 1**: Causative agents and their susceptibility patterns of monomicrobial NFGN-BSI during 2013-2016 in three tertiary teaching hospitals from northern Italy*.

|                         | N     | MDR   | XDR    | PDR   | CR     | DTR   |
|-------------------------|-------|-------|--------|-------|--------|-------|
| *Pseudomonas aeruginosa*| 258   | 15 (5.8) | 53 (20.5) | /     | 82 (31.8) | 35 (13.6)  |
| *Acinetobacter baumannii*| 59    | 0     | 37 (62.7) | 1 (1.7) | 38 (64.4) | 38 (64.4)  |
| *Stenotrophomonas maltophilia*| 38    | /     | /      | /     | 1 (2.6)  | 2 (5.3)   |

*Resistance categories (MDR, XDR, PDR) were mutually exclusive while antibiotic class resistances (CR) and new definition (DTR) were not.

Abbreviations: CR carbapenem resistance; DTR difficult-to-treat resistance; MDR multidrug-resistance; PDR pandrug-resistance, XDR extensively drug-resistance.

**Table 2. Univariate analysis of risk factors for all-cause 30-day mortality**
|                                | Total                  | Survivors              | Non-survivors          | p     |
|--------------------------------|------------------------|------------------------|------------------------|-------|
|                                | N= 355 (%)             | N= 293 (%)             | N= 62 (%)              |       |
| **Demographics**               |                        |                        |                        |       |
| Age (years) (median, IQR)      | 67 (55-79)             | 67 (54-78)             | 73 (61-84)             | 0.016 |
| Male sex                       | 233 (65.6)             | 194 (66.2)             | 39 (62.9)              | 0.66  |
| **Comorbidities**              |                        |                        |                        |       |
| Charlson index (median, IQR)   | 5.7 (3.6-7.4)          | 5.2 (3.5-7.1)          | 6.25 (4-9)             | 0.034 |
| Immunosuppression              | 87 (24.5)              | 74 (25.3)              | 13 (21)                | 0.52  |
| **Ward of admission**          |                        |                        |                        | 0.22  |
| Medical                        | 210 (59.2)             | 176 (60.1)             | 34 (54.8)              |       |
| ICU                            | 80 (22.5)              | 61 (20.8)              | 19 (30.6)              |       |
| Surgical                       | 65 (18.3)              | 56 (19.1)              | 9 (14.5)               |       |
| **Site of BSI acquisition**    |                        |                        |                        | 0.078 |
| Community acquired             | 71 (20.0)              | 65 (22.2)              | 6 (9.7)                |       |
| Healthcare associated          | 35 (9.9)               | 27 (9.2)               | 8 (12.9)               |       |
| Hospital acquired              | 249 (70.1)             | 201 (68.6)             | 48 (77.4)              |       |
| CRE carrier at BSI onset       | 44 (12.1)              | 35 (11.9)              | 9 (14.5)               | 0.462 |
| **Clinical severity at BSI onset** |                        |                        |                        |       |
| SOFA (median, IQR)             | 3 (2-5)                | 3 (2-5)                | 4 (3-6)                | 0.005 |
| Septic shock                   | 59 (16.6)              | 38 (13)                | 21 (33.9)              | 0.001 |
| **Source of BSI**              |                        |                        |                        |       |
| Undefined                      | 183 (51.5)             | 150 (51.2)             | 33 (53.2)              | 0.782 |
| CVC related                    | 102 (28.7)             | 86 (29.4)              | 16 (25.8)              | 0.645 |
| Lower respiratory tract        | 49 (13.8)              | 39 (13.3)              | 10 (16.1)              | 0.686 |
| Biliary tract                  | 41 (11.5)              | 34 (11.6)              | 7 (11.3)               | 1     |
| Urinary tract | 31 (8.7) | 27 (9.2) | 4 (6.5) | 0.624 |
| Intra-abdominal | 18 (5.1) | 16 (5.5) | 2 (3.2) | 0.551 |
| Complicated BSI | 38 (10.7) | 27 (12.9) | 11 (21.6) | 0.125 |

**Etiology**

| Etiology | 258 (72.7) | 222 (75.8) | 36 (58.1) | 0.005 |
| Pseudomonas aeruginosa | | | |
| Acinetobacter baumannii | 59 (16.6) | 41 (14) | 18 (29) | 0.005 |
| Stenotrophomonas maltophilia | 38 (10.7) | 30 (10.2) | 8 (12.9) | 0.651 |

**Resistance phenotypes***

| Resistance phenotypes | 34 (9.6) | 22 (8.4) | 12 (22.2) | 0.005 |
| MDR | 58 (16.3) | 46 (17.5) | 12 (22.2) | |
| XDR | |

**Antibiotic class resistance***

| Antibiotic class resistance | 95 (26.7) | 77 (26.3) | 18 (29) | 0.752 |
| ECR | 78 (22) | 55 (18.8) | 23 (37.1) | 0.002 |
| BL/BLIR | 124 (34.9) | 93 (31.7) | 31 (50) | 0.008 |
| CR | 144 (40.6) | 107 (36.5) | 37 (59.7) | 0.001 |
| FQR | 98 (27.6) | 69 (26.4) | 29 (51.8) | <0.001 |
| AminoglycosidesR | 53 (14.9) | 39 (21.9) | 14 (29.2) | 0.337 |
| TMP/SMXR | 5 (1.4) | 5 (1.7) | 0 (0) | 0.592 |
| COLIR | |

**New definition***

| New definition | 75 (21.1) | 52 (17.7) | 23 (37.1) | 0.001 |
| DTR | |

**Therapeutic management**

| Therapeutic management | 148 (41.7) | 119 (40.6) | 29 (46.8) | 0.397 |
| ID Consultation | 131 (36.9) | 111 (37.9) | 20 (32.3) | 0.470 |
| Source control | 125 (35.2) | 111 (38.4) | 14 (23.7) | 0.037 |
| Appropriate empirical therapy | 55 (15.5) | 42 (18.9) | 13 (29.5) | 0.152 |
| Combination empirical therapy | 16 (4.5) | 16 (12.8) | 0 | 0.223 |
| 2 in vitro active combination empirical therapy | |

Page 13/16
|                              |          |          |          |          |
|------------------------------|----------|----------|----------|----------|
| Appropriate definitive therapy | 262 (73.8) | 222 (76.8) | 40 (67.8) | 0.184    |
| Combination definitive therapy | 115 (32.4) | 89 (32) | 26 (47.3) | 0.031    |
| 2 in vitro active combination definitive therapy (with drugs) | 58 (16.3) | 48 (20.7) | 10 (23.8) | 0.682   |

* Resistance categories were mutually exclusive while antibiotic class resistances and new definition (DTR) were not.

Abbreviations: BL/BLIR betalactam/betalactamase inhibitor resistance; BSI bloodstream infection; COLIR Colistin resistance, CR carbapenem resistance; CRE carbapenem-resistant Enterobacteriaceae; CVC central venous catheter; DTR difficult-to-treat resistance; ECR extended-spectrum cephalosporin resistance; FQR fluoroquinolone resistance; ICU intensive care unit; IQR interquartile range; ID Consultation Infectious Disease Consultation, MDR multidrug-resistance; SOFA sequential organ failure assessment; TMP/SMXR Trimethoprim/sulfamethoxazole resistance, XDR extensively drug-resistance.

**Figures**

N=527 patients hospitalized during 2013-2016, diagnosed with NFGN-BSI

172 cases excluded:
N=146 polymicrobial bacteremia
N=26 clinical data were not available

355 patients (177 from Bologna, 155 from Turin, 23 from Genova) were analysed
Figure 1
Flow diagram of study population.

![Flow diagram showing incidence of P. aeruginosa and A. baumannii BSI over 2013-2016 years for Total, Sant'Orsola, Molinette, and San Martino.]

Figure 2
Overall incidence of P. aeruginosa and A. baumannii BSI per 1000 patient days between 2013-2016 years.

![Graphs showing susceptibility rates of P. aeruginosa and A. baumannii and S. maltophilia for various antibiotics.]
Figure 3

Susceptibility rates to individual antibiotic categories for Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia. Abbreviations: BL/BLI betalactam/betalactamase inhibitor, ESC extended-spectrum cephalosporin, FQ fluoroquinolone resistance;

![Figure 3](image)

Figure 4

Antibiotic management of NFGN-BSI.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TablesAdditional.docx